You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Intraocular inflammation with intravitreal bevacizumab (Avastin)
  1. Muhammad S Raja,
  2. Craig Goldsmith,
  3. Benjamin J L Burton
  1. James Paget University Hospital NHS Foundation Trust, Great Yarmouth, UK
  1. Correspondence to Mr Muhammad S Raja, James Paget University, Hospital NHS Foundation Trust, 1 Salk Road, Gorleston, Great Yarmouth NR31 7RL, UK; docraja{at}hotmail.com

https://doi.org/10.1136/bjo.2009.166033

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We congratulate Georgopoulos et al,1 for their excellent paper on intraocular inflammation with use of intravitreal bevacizumab (Avastin). Along with the efficacy, safety and tolerability is a key issue with the use of anti-VEGF agents,2 3 as ranibizumab (Lucentis) is now the standard of care for neovascular age-related macular degeneration according to NICE UK recommendations.4 5 However, the spectrum of off-label therapeutic indications for anti-VEGF agents …

    View Full Text

    Footnotes

    • Linked articles 166918

    • Competing interests None.

    • Provenance and peer review Not commissioned; not externally peer reviewed.

    Linked Articles

    • PostScript
      Authors' response
      Michael Georgopoulos Kaija Polak Franz Prager Christian Prünte Ursula Schmidt-Erfurth
      British Journal of Ophthalmology 2010; 94 525-525 Published Online First: 12 Apr 2010. doi: 10.1136/bjo.2009.166918